X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15793) 15793
Magazine Article (31) 31
Book Chapter (13) 13
Book / eBook (7) 7
Dissertation (6) 6
Book Review (4) 4
Publication (3) 3
Web Resource (3) 3
Conference Proceeding (2) 2
Newspaper Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11229) 11229
indoles - therapeutic use (8278) 8278
male (6464) 6464
animals (6022) 6022
female (5491) 5491
indoles - pharmacology (4907) 4907
middle aged (3612) 3612
pharmacology & pharmacy (2938) 2938
oncology (2881) 2881
adult (2728) 2728
aged (2717) 2717
mice (2629) 2629
indoles - adverse effects (2160) 2160
antineoplastic agents - therapeutic use (2144) 2144
cancer (2139) 2139
indoles - administration & dosage (2133) 2133
pyrroles - therapeutic use (2045) 2045
rats (1982) 1982
treatment outcome (1962) 1962
cell line, tumor (1561) 1561
dose-response relationship, drug (1368) 1368
indoles - chemistry (1348) 1348
sunitinib (1295) 1295
apoptosis (1186) 1186
analysis (1177) 1177
care and treatment (1150) 1150
expression (1080) 1080
carcinoma, renal cell - drug therapy (1072) 1072
kidney neoplasms - drug therapy (1033) 1033
research (1009) 1009
biochemistry & molecular biology (995) 995
neurosciences (995) 995
sulfonamides - therapeutic use (911) 911
double-blind method (910) 910
disease models, animal (905) 905
therapy (864) 864
antineoplastic agents - pharmacology (863) 863
time factors (855) 855
indoles (837) 837
aged, 80 and over (830) 830
tumors (818) 818
indoles - pharmacokinetics (811) 811
chemistry, medicinal (802) 802
drug therapy (794) 794
apoptosis - drug effects (793) 793
proteins (790) 790
indole (769) 769
cell biology (755) 755
protein kinase inhibitors - therapeutic use (731) 731
rats, sprague-dawley (725) 725
chemotherapy (719) 719
metastasis (717) 717
cell proliferation - drug effects (713) 713
activation (711) 711
clinical trials as topic (711) 711
efficacy (696) 696
health aspects (696) 696
mutation (692) 692
antineoplastic agents - adverse effects (689) 689
medicine & public health (688) 688
inhibition (678) 678
kinases (672) 672
research article (661) 661
survival (655) 655
angiogenesis inhibitors - therapeutic use (646) 646
medicine (644) 644
pyrroles - adverse effects (643) 643
in-vitro (642) 642
cells (637) 637
kidney neoplasms - pathology (634) 634
antineoplastic combined chemotherapy protocols - therapeutic use (620) 620
niacinamide - analogs & derivatives (620) 620
angiogenesis (612) 612
multidisciplinary sciences (602) 602
drug therapy, combination (599) 599
fatty acids, monounsaturated - therapeutic use (583) 583
antineoplastic agents (582) 582
pyrroles - pharmacology (574) 574
tyrosine kinase inhibitor (574) 574
double-blind (573) 573
neoplasms - drug therapy (568) 568
melanoma - drug therapy (566) 566
pyrroles - administration & dosage (565) 565
clinical neurology (554) 554
adolescent (553) 553
melanoma (553) 553
pharmacology (553) 553
indoles - metabolism (551) 551
signal transduction - drug effects (551) 551
endothelial growth-factor (550) 550
pharmacology/toxicology (545) 545
antimitotic agents (530) 530
cell survival - drug effects (517) 517
cells, cultured (514) 514
disease-free survival (509) 509
inhibitors (509) 509
urology & nephrology (508) 508
chemistry, multidisciplinary (502) 502
mice, inbred c57bl (498) 498
phosphorylation (498) 498
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15029) 15029
Japanese (227) 227
German (193) 193
French (163) 163
Russian (144) 144
Chinese (82) 82
Spanish (61) 61
Italian (40) 40
Polish (33) 33
Czech (21) 21
Hungarian (19) 19
Dutch (13) 13
Danish (8) 8
Portuguese (4) 4
Hebrew (3) 3
Norwegian (3) 3
Romanian (3) 3
Slovak (3) 3
Korean (2) 2
Lithuanian (2) 2
Swedish (2) 2
Croatian (1) 1
Finnish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2011, Volume 2013, Issue 1, p. CD006626
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
Chest, ISSN 0012-3692, 03/2016, Volume 149, Issue 3, pp. 756 - 766
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007360
Background Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to... 
Piperazines | Plant Extracts | Benzilates | Adrenergic alpha‐Antagonists | Urology | Alpha‐blockers/Alpha‐1 adrenoceptors/Alpha antagonists/5‐alpha reductase inhibitors | Naphthalenes | Randomized Controlled Trials as Topic | Prostatic Hyperplasia | Urological Agents | Tamsulosin | Lower Urinary Tract Symptoms | Sulfonamides | Quality of Life | Prostatism | Benign prostatic hyperplasia | Treatment of Benign Prostatic Hyperplasia | Ethamsylate | Indoles | Pharmacologic/Medical Therapies | Medicine General & Introductory Medical Sciences | Drug Combinations | Naftopidil | Benign Prostatic Hyperplasia/Obstruction (Hypertrophy, Prostatic Hyperplasia) | Naphthalenes [adverse effects; therapeutic use] | 75 MG | EFFICACY | Prostatic Hyperplasia [complications] | STORAGE SYMPTOM | SEXUAL FUNCTION | CLINICAL PROGRESSION | MEDICINE, GENERAL & INTERNAL | OVERACTIVE BLADDER | Sulfonamides [adverse effects; therapeutic use] | Piperazines [adverse effects; therapeutic use] | ALPHA-ADRENOCEPTOR ANTAGONISTS | Adrenergic alpha-Antagonists [adverse effects; therapeutic use] | Prostatism [drug therapy; etiology] | TAMSULOSIN HYDROCHLORIDE | ALPHA-1 BLOCKERS | HEALTH-STATUS | Benzilates - adverse effects | Naphthalenes - adverse effects | Benzilates - therapeutic use | Humans | Adrenergic alpha-Antagonists - therapeutic use | Male | Prostatic Hyperplasia - complications | Prostatism - drug therapy | Urological Agents - adverse effects | Adrenergic alpha-Antagonists - adverse effects | Ethamsylate - therapeutic use | Lower Urinary Tract Symptoms - drug therapy | Lower Urinary Tract Symptoms - etiology | Ethamsylate - adverse effects | Urological Agents - therapeutic use | Prostatism - etiology | Tamsulosin - adverse effects | Tamsulosin - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Plant Extracts - therapeutic use | Naphthalenes - therapeutic use | Plant Extracts - adverse effects
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 02/2008, Volume 15, Issue 5, pp. 422 - 432
...) for growth factors, are among the best targets for this type of therapeutic approach. Two classes of compounds targeting RTKs are currently used in clinical practice... 
Monoclonal antibodies | Small molecules | Tyrosine kinase receptors | Targeted therapy | Cancer therapy | Tyrosine kinase inhibitors | targeted therapy | CHEMISTRY, MEDICINAL | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | BCR-ABL | MONOCLONAL-ANTIBODY | CHRONIC MYELOID-LEUKEMIA | tyrosine kinase inhibitors | CELL LUNG-CANCER | BREAST-CANCER | tyrosine kinase receptors | cancer therapy | PHASE-II TRIAL | IN-VIVO | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | GASTROINTESTINAL STROMAL TUMORS | small molecules | monoclonal antibodies | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Bevacizumab | Antibodies, Monoclonal, Humanized | Sunitinib | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Lapatinib | Cetuximab | Gefitinib | Pyrroles - therapeutic use | Pyridines - therapeutic use | Clinical Trials as Topic | Piperazines - therapeutic use | Enzyme Inhibitors - therapeutic use | Imatinib Mesylate | Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Sorafenib | Indoles - therapeutic use | Benzamides | Trastuzumab | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
World journal of urology, ISSN 1433-8726, 2016, Volume 35, Issue 2, pp. 179 - 188
Journal Article